A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655
ZOLL Medical Corporation
+1 (978) 421-9637
ZOLL AUTOPULSE CITED FOR IMPROVED PRE-HOSPITAL OUTCOMES AT AHA SCIENTIFIC SESSIONS 2009
California Registry for ZOLL AutoPulse Revealed Higher Rates of ROSC; Charleston County EMS Improves Short-Term Outcome During Transport
November 23, 2009—CHELMSFORD, MASS.—ZOLL Medical Corporation (Nasdaq GS: ZOLL) announced today that the importance of continuous, consistent chest compressions provided by ZOLL’s AutoPulse® Non-invasive Cardiac Support Pump in the improvement of short-term outcomes was presented in two separate poster presentations at the American Heart Association’s Resuscitation Science Sessions in Orlando Florida last week.
David Ghilarducci, M.D., and Cesar Aristeiguieta, M.D., Members of the California AutoPulse Registry Steering Committee reported in a poster presentation “The Potential for Enhanced Near-Term Outcomes with Mechanical CPR” that registry data showed patients treated with AutoPulse (A-CPR) had a higher return of spontaneous circulation (ROSC) than those receiving manual CPR (M-CPR).
The California AutoPulse Quality Assurance Registry was established to undertake data collection related to the rate of emergency department admissions and adverse events associated with CPR provided by the AutoPulse in conjunction with the introduction of the new mechanical CPR device in California. More than 1,020 patients were included in the Registry between April 2007 and June 2009 by 32 emergency medical services agencies using the AutoPulse to provide mechanical CPR support in California. The results revealed that adverse events were rare; only 6 A-CPR (0.8%) treated patients reported events. Overall rate of ROSC was improved for A-CPR vs. M-CPR both in the field (31% to 21%, p=0.002) and ROSC sustained to ED admission (25% to 18%, p=0.014).
Don Lundy, B.S., NREMT-P, and Todd McGeorge, B.A. NREMT-P of Charleston County EMS, North Charleston, N.C. reported in “Mechanical Chest Compressions Improve Short-Term Outcome in Patients Requiring CPR During Transport” that patients treated with mechanical chest compressions were more likely to achieve return of spontaneous circulation (ROSC) during transport compared with patients treated with manual chest compressions (CC).
The authors report that over the study period, the agency gradually equipped their ambulances with the AutoPulse (LDB-CC) to achieve continuous, consistent chest compressions during transport; thus, 50% of patients were treated with LDB-CC and 50 % were treated with manual CC. Overall, 55 (11%) patients achieved ROSC for the first time during transport and patients treated with LDB-CC were more likely to achieve ROSC during transport than patients treated with manual CC (14.3% vs. 6.7%, p=0.005). Of the 55 patients that achieved ROSC during transport, 44 (80%) qualified for transport according to ALS termination of resuscitation protocols.
“We are pleased to see resuscitation outcomes improve in the pre-hospital setting where our AutoPulse is being used,” said Jonathan A. Rennert, President of ZOLL. “The implementation of the AutoPulse in this setting adds the advantage of continuous consistent chest compressions while improving provider safety during transport.”
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe.
For more information, visit www.zoll.com.
Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL and AutoPulse are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.